Godavari Biorefineries Share Price Surges Over 8% After Securing US Patent for Anti-Cancer Compounds

Godavari Biorefineries Limited has achieved a significant milestone with the granting of a US patent for its innovative anti-cancer compounds.  

These compounds, designed to inhibit unregulated cell growth, particularly target cancer stem cells and have shown promise in treating various cancers, including breast and prostate cancer. 

Breakthrough in Cancer Treatment 

The newly patented compounds by Godavari Biorefineries represent a breakthrough in cancer treatment. By focusing on cancer stem cells, these compounds aim to tackle the root cause of cancer proliferation, offering a potential new avenue for therapy.  

The patent, titled "Compounds for the Inhibition of Unregulated Cell Growth," outlines the synthesis process and biological activity of these novel chemical entities. 

The patent, filed under application number 17/415,676, was initially submitted on December 16, 2019, and has now been officially granted. This development underscores the company's commitment to advancing cancer research and treatment options. 

Patent Details and Implications 

The patent, identified as US 12,459,930 B2, extends Godavari Biorefineries' intellectual property rights in the US, allowing them to exclude others from making, using, or selling the invention. This strategic move not only strengthens their market position but also opens up potential collaborations and licensing opportunities. 

The compounds, covered under various international classifications, are designed to inhibit uncontrolled cell proliferation. This innovation could potentially revolutionise the way cancer is treated, offering hope to millions of patients worldwide. 

Read More: Apollo Micro Systems Share Price in Focus on Securing 15-Year Defence License for Manufacturing! 

Godavari Biorefineries Portfolio  

With the US patent secured, Godavari Biorefineries is poised to explore commercialisation opportunities. The patent's extension by 941 days underlines the significance of this innovation in the pharmaceutical landscape. As the company continues to develop these compounds, the potential for partnerships with global pharmaceutical firms could enhance their market reach. 

Furthermore, the patent strengthens Godavari Biorefineries' portfolio, positioning them as a key player in the anti-cancer segment. This achievement not only highlights their research capabilities but also sets the stage for future advancements in cancer treatment. 

Godavari Biorefineries Share Price Performance  

As of December 05, 2025, at 1:54 PM, Godavari Biorefineries share price on NSE was trading at ₹264.00 up by 10.52% from the previous closing price. 

Conclusion 

Godavari Biorefineries' acquisition of a US patent for its anti-cancer compounds marks a pivotal moment in their research and development efforts. By targeting cancer stem cells, these compounds offer a promising approach to cancer treatment, potentially transforming patient outcomes. This patent not only enhances their intellectual property portfolio but also opens doors for future collaborations and market expansion. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.